Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis—Analyses of Phase 2b Study to Support Selection of Phase 3 Doses

Upadacitinib is a selective Janus kinase 1 inhibitor that was recently approved for treatment of rheumatoid arthritis and is currently being evaluated for treatment of several other autoimmune diseases, including atopic dermatitis (AD). The relationships between upadacitinib plasma exposure and effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Mohamed‐Eslam F., Gopalakrishnan, Sathej, Teixeira, Henrique D., Othman, Ahmed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Exposure Response
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049015/
https://www.ncbi.nlm.nih.gov/pubmed/33156550
http://dx.doi.org/10.1002/jcph.1782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049015/
https://www.ncbi.nlm.nih.gov/pubmed/33156550
http://dx.doi.org/10.1002/jcph.1782

Ejemplares similares